72 results about "Serum amyloid A" patented technology

The invention discloses a serum amyloid A assay kit and a preparation method thereof. The kit includes reagent R1 and reagent R2 two-liquid components independent of each other, wherein the reagent R1 component includes buffer solution 1 and reagent R2 Components include buffer 2 and SAA antibody latex beads. The serum amyloid A assay kit of the invention has the advantages of simple operation, rapid response, high sensitivity and good specificity.

Described are methods of assessing whether a subject has or is at risk of having multiple organ amyloidosis (MOA) The method includes detecting a diagnostically predictive collection of biomarkers of multiple organ amyloidosis, wherein the detection of a diagnostically predictive collection of biomarkers indicates the subject has or is at risk of having multiple organ amyloidosis Also described are methods of monitoring treatment of subjects with multiple organ amyloidosis and evaluating therapeutic compounds Representative biomarkers for use in the methods may be selected from variant serum amyloid A (SAA) allele, elevated SAA level, elevated C-reactive protein (CRP) level, depressed glycosammoglycan (GAG) level, elevated interleukin-18 (IL-18) level, elevated macrophage-colony stimulating factor (M-CSF) level, elevated hepatocyte growth factor (HGF) level, presence of an antibody against citrullmated vimentm (Sa), presence of a monoclonal immunoglobulin light chain, increased serum albumin, and increased creatinine clearance

The invention discloses a double detection line SAA (Serum amyloid A protein) immunofluorescence chromatography quantitative detection reagent and a preparation method thereof. The double detection line SAA immunofluorescence chromatography quantitative detection reagent can simultaneously promote sensitivity and detection scope and can be applied to clinical detection for SAA level in patients of acute inflammation and chronic inflammation. According to the technical key points, the reagent comprises a base plate, a combining cushion, a coating film and an absorbing cushion, wherein a sample cushion is connected with the base plate; anti-SAA monoclonal antibody 1 and chick IgY are sprayed on the combining cushion and are marked with a same fluorescent microsphere; a detection line T1, a detection line T2 and a quality control C line are arranged on the coating film; anti-SAA monoclonal antibody 2 is coated with the detection line T1; antigen SAA protein is coated with the detection line T2; goat-anti-chick IgY is coated with the quality control C line. The reagent belongs to the technical field of in-vitro diagnostic reagents.

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and / or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and / or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.

The invention discloses an immunofluorescence chromatography kit for quantitatively detecting SAA, CRP, and PCT and a preparation method thereof, which includes a fluorescent immunochromatography test strip and a fluorescent substance. Nitrocellulose membrane, one end of the nitrocellulose membrane is connected with a sample pad, and the other end of the nitrocellulose membrane is connected with an absorption pad; the nitrocellulose membrane is provided with detection lines for detecting the contents of SAA, CRP, and PCT in parallel. ; The fluorescent substance includes a fluorescent substance coupled to a rabbit IgG polyclonal antibody, a fluorescent substance coupled to a paired SAA monoclonal antibody, a fluorescent substance coupled to a paired CRP monoclonal antibody, and a paired PCT monoclonal antibody. of fluorescent substances. This kit can simultaneously detect the contents of SAA, CRP, and PCT conveniently, accurately, and with high sensitivity.

The invention relates to a kit for quickly and quantificationally detecting serum amyloid A (SAA) by using an immunogold method. The kit includes lyophilized anti-SAA immunogold, a reaction plate, a sample diluent, a lyophilized colloidal gold complex solution, a scrubbing solution and a sealing solution. The preparation method comprises the following steps: (1) firstly preparing a conjugate of the colloidal gold and anti-SAA immunogold, and preparing lyophilized anti-SAA immunogold; and (2) preparing the sample diluent, the lyophilized colloidal gold complex solution, the scrubbing solution and the sealing solution according to the proportion, preparing the reaction plate, and assembling the prepared objects to a finished product to obtain the kit. By using the kit provided by the invention, a doctor can obtain an SAA measurement result on the spot when a person is ill so as to quickly judge the patient's condition, so that more targeted treatment can be effectively taken on the patient, healing time is shortened and medical cost is reduced. The kit provided by the invention has a good application prospect.

RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.

Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and / or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and / or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.

This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-BI, which is also referred to as CLA-1 (SR-BI / CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SRB I / CLA-1 ligands contributing to the pathogenesis of disease include LPS, LTA, viral envelope proteins, beta-amyloid, serum Amyloid A and / or heat shock proteins.

The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.

The invention relates to the technical field of biology, and specifically relates to a reagent kit for measuring a serum amyloid A (SAA) concentration, and a preparation method for the reagent kit formeasuring the SAA concentration. The invention applies the following technical solution: a reagent kit for measuring an SAA concentration is characterized in that the reagent kit for measuring the SAA concentration includes a reagent R1 and a reagent R2, the reagent R1 includes a buffer solution, an accelerator and a preservative, the reagent R2 includes a buffer solution, a stabilizer, a latex microsphere to which SAA polyclonal antibody-biotin-streptavidin is coupled, and a preservative. The reagent kit for measuring the SAA concentration has the following advantage: the reagent kit for measuring the SAA concentration of the invention applies the latex microsphere connected with the streptavidin in a ratio of 1:1, and the SAA antibody connected with the biotin in a ratio of 1:2, and ina ratio of 1:1, the latex microsphere connected with the streptavidin is further mixed and reacted with the SAA antibody connected with the biotin, thus the repeatability and sensibility can be improved evidently and the linear range can achieve 5-400 mg / L.

The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB.

The invention relates to the technical field of fluorescence immunoassay in medical immunology, and in particular relates to a serumamyloid A (SAA) testing kit (fluorescence immunochromatographic method) and a manufacturing method. The kit is provided with a test paper card. The kit is characterized in that a PVC (Polyvinyl Chloride) plate, a sample pad, a conjugate pad, a nitrocellulose membrane and a water absorbing pad are sequentially arranged on the test paper card from bottom to top; a rare-earth Eu<3+> fluorescent microsphere marked serum amyloid A monoclonal antibody is adsorbed on the conjugate pad; the diameter of a rare-earth fluorescent microsphere is 200nm; the rare-earth fluorescent microsphere contains a rare-earth lanthanide element Eu<3+>; the rare-earth fluorescent microsphere is stable in a ground state and emits fluorescence of which the wavelength is 615nm under the stimulation action of laser of 337nm; and the monoclonal antibody is a monoclonal antibody which is purified and mixed, and comes from a monoclonal antibody cell strain for 2-6 different serum amyloid A epitopes. The kit has the advantages of being simple and convenient to operate, rapid in reaction, high in sensitivity, good in specificity and the like.

The invention discloses a latex-enhanced immune turbidimetric detection reagent for serum amyloid A (SAA‑Serum Amyloid A). The reagent is a single reagent, and the main component of the reagent is latex particles labeled with SAA antibody, and also includes buffer solution, surfactant, salt, stabilizer, suspending agent and preservative. The invention also discloses a method for using the reagent to detect the concentration of serum amyloid A (SAA) in blood samples by the principle of transmission or scattering turbidimetry. The invention adopts a single reagent, is simple to operate, does not need to be mixed, has high sensitivity, and has a wide linear range, and can directly measure various samples such as whole blood, serum, and plasma, and can be widely used in various transmission or scattering analyzers, including ordinary biochemical analyzers , specific protein analyzers, etc.

The invention provides a fluorescence immunosorbent assay kit for joint detection of SAA (Serum Amyloid A) and CRP (C-reactive protein) based on two-color quantum dots and a preparation method of thefluorescence immunosorbent assay kit, and belongs to the technical field of in vitro diagnostic detection. According to the fluorescence immunosorbent assay kit, the advantages of quantum dot multicolor marking and the characteristics of antibody antigen specific reaction are fully utilized; and two antibodies are coated onto the same enzyme coated plate hole to form two kinds of double antibody sandwich methods of coated antibody-to-be-tested antigen-quantum dot labeled antibodies, and a novel simple, sensitive and stable detection method of various markers is established. Compared with a traditional ELISA (Enzyme-linked immunosorbent assay) method, the method has the advantages that the use amount of detection samples is reduced and the detection time is shortened; in addition, the detection efficiency can be improved; the detection cost is favorably saved; and the medical cost is reduced.

The invention discloses an SAA (serum amyloid A) immunochromatographic test strip and a preparation method and a test method thereof. The test strip comprises a sample pad, a combination pad, an analyzing membrane, a water-absorbing pad, a bottom board, a testing tape T line and a quality control tape C line, wherein the analyzing membrane is adhered on the upper portion of the bottom board, the combination pad and the water-absorbing pad are adhered at two ends of the upper portion of the analyzing membrane respectively, the sample pad is adhered at one end of the upper portion of the combination pad, and the testing tape T line and the quality control tape C line are adhered on the analyzing membrane. The SAA immunochromatographic test strip and the preparation method and the test method thereof have the advantages that anti-SAA antibody protein is used for achieving rapid testing of high sensitivity and high specificity of SAA antibodies in a sample by indirect immunoassay, so that bases for auxiliary diagnosis of diseases such as infectious diseases, tissue damage necrotic diseases, atherosclerotic diseases, immune diseases and rejection after organ transplantation are provided.

The invention provides a quick and accurate cow recessive endometritis early diagnosis kit. The kit is assembled by serum amyloid A (SAA), interleukin-6 (IL-6) and IL-8 standard antibody enveloped ELISA plates, a novel monoclonal antibody serving as a competitive antibody, a horse radish peroxidase labeled secondary antibody and the like, and can be prepared by preparing SAA, IL-6 and IL-8 antibodies, the horse radish peroxidase labeled secondary antibody, an enzyme-linked immuno sorbent assay (ELISA) reagent and an ELISA plate. In the kit, an ELISA method is mainly adopted. The ELISA method has a wide application range and high operation speed and can eliminate certain vaccine reactions; by the method, a result can be acquired in two minutes; and the kit can be used for laboratory detection, pasture operation and field operation and is suitable for clinical detection and farmer on-site detection.

The invention relates to a fluorescence immunochromatography assay kit and a using method thereof, and belongs to the technical field of products for diagnosing animal epidemic diseases in vitro. Thekit comprises a plastic card shell, a detection reagent card and sample diluent, wherein the card shell comprises a bottom shell and an upper cover, a test strip clamping groove is formed in the bottom shell, and a scanning window and a sample adding hole are formed in the upper cover; the detection reagent card consists of a sample pad, a combination pad, a nitrocellulose membrane and absorbent paper which are sequentially adhered to a bottom plate; and the position of the scanning window is matched with that of the nitrocellulose membrane, and the position of the sample adding hole is matched with that of the sample pad. The kit provided by the invention can be used for judging whether a dairy cow suffers from mastitis or the severity of mastitis of the dairy cow by detecting the contentof serum amyloid A in milk, and has the characteristics of rapidness, accuracy and low cost.

The invention discloses a kit for measuring serum amyloid A and a preparation method of the kit. The kit comprises two independent liquid components, namely a reagent R1 and a reagent R2, wherein the reagent R1 comprises the following ingredients by content: a buffer, inorganic salt ions, a coagulant, a preservative and a stabilizer; the reagent R2 comprises the following ingredients: the buffer, the stabilizer, the preservative, and a latex-coated anti-serum amyloid A antibody. The preparation method comprises the following steps: preparing the reagents according to the contents of the ingredients; mixing a to-be-tested sample with the reagent R1 and the reagent R2; measuring absorbance variation with a fully automatic biochemical analyser; calculating the concentration of serum amyloid A in the sample according to the absorbance variation. The kit and the preparation method have the advantages of high measurement accuracy and the like.

Novel colostrum associated mammalian Serum Amyloid A (SAA) promoter sequences are disclosed. These promoters can be used in transgenic protocols for tissue specific expression and expression constructs, vectors and host cells are disclosed. Also the regulatory features of these promoters in colostrum associated SAA productions are exploited to treat disease states associated with or influenced by colostrum associated SAA production.

The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

The invention discloses a test strip for immunochromatography-based rationed joint detection of C-reactive protein and serum amyloid A and a manufacture method of the test strip. The test strip comprises a clamp shell, a bottom plate, a sample pad, a fluorescence indicator combination pad, a nitrocellulose membrane and a water-absorbing pad, and is formed by sequentially adhering the sample pad, the fluorescence indicator combination pad, the nitrocellulose membrane and the water-absorbing pad to the bottom plate in a lap joint mode. The fluorescence indicator combination pad comprises streptavidin-labeled fluorescent protein, biotin-labeled C-reactive protein monoclonal antibodies, and biotin-labeled serum amyloid A monoclonal antibodies. Detection lines and quality control lines are arranged on the nitrocellulose membrane. The test strip and the manufacture method thereof have the advantages that the rapid rationed joint detection of the C-reactive protein / the serum amyloid A is realized through combination between a fluorescent protein indicator and a 'streptavidin-biotin amplification system'; detection time is shortened greatly, detection sensitivity is improved, and convenience and reliability are improved greatly through joint detection.

A genomic nucleotide sequence encoding Serum Amyloid A (SAA), isolated and purified from mammalian colostrum, is disclosed. Methods of use for the same in transgenic protocols is also disclosed.

The invention discloses a serum amyloid A (SAA) protein and an encoding gene and an application thereof. The serum amyloid A protein is characterized in that a nucleotide sequence of the serum amyloid A protein is as showed in the 148-567th basic groups of SEQ ID NO.1, and the amino acid sequence of the serum amyloid A protein is as shown in SEQ ID NO.2. The gene is firstly discovered in a mollusk, and at present, the gene is discovered in vertebrates and is only discovered in an echinodermata in invertebrates. The quantitative PCR experiment proves that the oyster SAA is remarkably up-regulated after bacterial infection and is similar to a mammal, and thus the gene is utilized as a gold standard for detecting the oyster physical condition. The gene can monitor the physical condition of the oyster at any time by detection, a positive accurate caution signal is provided for the oyster disease prevention, and the expansion of a disaster is prevented. The application of the technology has the advantages that the germplasm innovation capability of the cultivated shellfish is further improved, and the efficient sustainable development of an industry is supported.

The invention discloses an SAA monoclonal antibody 03-7-3, the heavy chain of the SAA monoclonal antibody 03-7-3 is IgG1, the light chain is k, and the amino acid sequences of the variable regions ofthe heavy chain and the light chain are respectively shown as SEQ ID NO. 3 and SEQ ID NO. 4. The SAA monoclonal antibody 03-7-3 disclosed by the invention can specifically identify disease-related SAA-ApoA1-HDL complex and SAA proteins, and on the basis of the SAA monoclonal antibody 03-7-3, an assay method for the SAA-ApoA1-HDL complex and the SAA proteins is established. The SAA-ApoA1-HDL complex is significantly associated with liver cirrhosis, and is a potential risk factor for the liver cirrhosis; and the concentration of the SAA proteins is significantly associated with the liver cirrhosis due to hepatitis B and liver cancer, and is a potential risk factor for the liver cirrhosis due to hepatitis B and the liver cancer. Therefore, the SAA monoclonal antibody 03-7-3 disclosed by the invention has important clinical value for the prediction of the potential risk of the liver cirrhosis and the liver cancer and the development of diagnostic markers for the diseases.

The invention provides a detection device for simultaneously and quantitatively detecting SAA / PCT / CRP. The detection device for simultaneously, rapidly and quantitatively detecting SAA / PCT / CRP is composed of human serum amyloid A (SAA) test paper, human procalcitonin (PCT) test paper, C-reactive protein (CRP) test paper, a triplicate card case and an immunochromatography interpretation result recorder carrying a corresponding judgment method and a standard curve, wherein the human serum amyloid A (SAA) test paper, the human procalcitonin (PCT) test paper and the C-reactive protein (CRP) test paper are independent. The detection device is suitable for on-site detection, a detection method is easy, convenient and stable, the situation that a large number of blood samples are extracted is not needed, medical cost is reduced, sensitivity is high, and SAA / PCT / CRP can be simultaneously, rapidly and quantitatively detected.

The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.